Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma Holdings, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Matinas BioPharma Holdings, Inc. (MTNB) is a Biotechnology company based in US with a market capitalization of $1.6M. Free cash flow was negative at -$7M. This page tracks MTNB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 3 employees · IPO Jul 21, 2014

Valuation

Valuation & price

$0.56as of May 17, 2026· -76.2% vs 52w high

P/E ratio

Latest-FY diluted EPS

0.32

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$2.13$1.23$0.33Jul 25Jan 26Jul 26
$0.3352-week range$2.36
Loading valuation history…

Fundamentals

Key fundamentals

$1.6M

Market cap

Revenue growth (YoY)

100.0%

Gross margin

-$7M

Free cash flow (USD)

-$2.6M

Net debt

Net cash position

12.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$0$0

Free cash flow by year

20162025

-$6.1M-$7M

Gross margin by year

20212023

-44090.9%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJul 13, 2026Filing

    Business Combination Agreement

  • 8-K eventJun 26, 2026Filing

    Delisting Notice

  • FinancingJun 16, 2026Filing

    Securities Registration

  • Quarterly reportMay 8, 2026Filing

    10-Q Filed

  • 8-K eventApr 3, 2026Filing

    Delisting Notice

Questions

Frequently asked questions

What is Matinas BioPharma Holdings, Inc.'s market cap?

Matinas BioPharma Holdings, Inc. (MTNB) has a market capitalization of $1.6M.

What is MTNB's P/E ratio?

A meaningful P/E ratio is not available for MTNB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MTNB's price-to-book (P/B) ratio?

MTNB trades at 0.32 times book value per share.

Are insiders buying MTNB stock?

SEC Form 4 filings show no open-market insider buys at Matinas BioPharma Holdings, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.